Episurf Medical (NASDAQ: EPIS B) today announces that a peer-reviewed article with clinical data on 10 Episealer® knee implant patients with 24 months’ follow-up now is accepted for publication.
The publication with the title “A customized femoral resurfacing metal implant for focal chondral lesions - radiostereometric analysis and subjective outcome of the first ten patients” by Stålman, A., Sköldenberg, O., Martinez-Carranza, N., Högström, M. and Ryd, L. will be published in the journal Knee Surgery, Sports Traumatology, Arthroscopy and is shortly available online.
The study behind the publication is a multi-center clinical study conducted in Sweden with Dr Anders Stålman as principal investigator. The surgeries were performed between 2012 and 2014. The patients were followed-up with subjective outcome measures (VAS, Tegner, EQ5D and KOOS) and implant fixation was studied with RSA. The subjective outcome measures showed improvements that reached significance for VAS (p=<â0,001), Tegner (p=0,034) and the KOOS sub-scores Activities of Daily Living (p=0,0048), Sport and Recreation (p=0,034) and Quality of Life (p=0,037).
“This first publication from a clinical multi-center study with Episealer®, a customized focal knee resurfacing system, shows short-term implant safety and the patient related outcome measures show good to excellent results” says Anders Stålman, PhD, Senior Consultant, Capio Artro Clinic, Stockholm.
“This publication is very welcome for us, as high-quality peer-reviewed clinical evidence is a must for orthopaedic surgeons in their treatment decisions. This is a further and very important step forward to gain market shares for the Episealer®” comments Pål Ryfors, CEO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 09.15 CET on 14 November 2017.